Subsequent reports based on pharmacovigilance data, post hoc analyses of randomised trials, and findings from observational studies indicate a potential link between GLP1 receptor agonists and thyroid cancer, although not conclusively. Here, GLP1R is linked to thyroid gland carcinoma.